Redeye interview regarding the positive phase 1b results
Date: 2024-02-05
Redeye has interviewed our CEO, Kristina Torfgård. They discussed the company's primary analysis of phase Ib study data with the vaccine candidate ALZ-101.
Redeye has interviewed our CEO, Kristina Torfgård. They discussed the company's primary analysis of phase Ib study data with the vaccine candidate ALZ-101.